ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

N4P N4 Pharma Plc

0.525
0.00 (0.00%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.525 0.45 0.60 0.525 0.525 0.525 10,000 08:00:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 2k -1.27M -0.0047 -1.11 1.4M

N4 Pharma PLC Result of AGM

23/05/2024 12:19pm

RNS Regulatory News


RNS Number : 6939P
N4 Pharma PLC
23 May 2024
 

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Result of Annual General Meeting

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

 

 

Resolution

For

For%

Against

Against%

Total

Witheld votes*

Ordinary Resolution 1

To receive the annual report and audited accounts for the year

ended 31 December 2023

20,612,844

99.93%

13,980

0.07%

20,626,824

296,841

Ordinary Resolution 2

To re-elect Nigel Theobald as a Director of the Company

20,605,744

99.32%

141,080

0.68%

20,746,824

176,841

Ordinary Resolution 3

To re-elect David Templeton as a Director of the Company

20,605,744

99.32%

141,080

0.68%

20,746,824

176,841

Ordinary Resolution 4

To re-appoint Saffery Champness LLP as the Companyʼs auditor

and to authorise the Directors to determine their remuneration

20,605,644

99.32%

140,980

0.68%

20,746,624

177,041

Ordinary Resolution 5

To authorise the Directors to allot shares

20,559,085

99.10%

187,539

0.90%

20,746,624

177,041

Special Resolution 6

To disapply pre-emption rights

20,506,310

99.00%

207,439

1.00%

20,713,749

209,916

 

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

investors.n4pharma.com

 

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

InvestorHub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

 

https://investors.n4pharma.com/link/Ky0AZe

 

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44(0)20 3657 0050

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBBGDUIBDDGSX

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Your Recent History

Delayed Upgrade Clock